Atlas Trials

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Clinical trial NCT04262466 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04262466
Sponsor
Immunocore Ltd
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Select Advanced Solid Tumors
Start date
2020-02-25
Primary completion
2026-10-01
Enrollment
410

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.